{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:23:15Z","timestamp":1784247795221,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Servier Group Italy"},{"DOI":"10.13039\/501100007642","name":"Universit\u00e0 degli Studi di Roma Tor Vergata","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007642","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s40261-024-01365-z","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T12:02:10Z","timestamp":1725883330000},"page":"739-747","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Economic Burden of Atherosclerotic Cardiovascular Disease in Italy"],"prefix":"10.1007","volume":"44","author":[{"given":"Francesco S.","family":"Mennini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Scortichini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furio","family":"Colivicchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo P.","family":"Maggioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8364-1895","authenticated-orcid":false,"given":"Paolo","family":"Sciattella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,9]]},"reference":[{"issue":"4","key":"1365_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1161\/CIRCRESAHA.115.307611","volume":"118","author":"W Herrington","year":"2016","unstructured":"Herrington W, Lacey B, Sherliker P, Armitage J, Lewington S. Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease. Circ Res. 2016;118(4):535\u201346.","journal-title":"Circ Res."},{"key":"1365_CR2","unstructured":"OECD\/European Observatory on Health Systems and Policies (2023), Italy: Country Health Profile 2023, State of Health in the EU, OECD Publishing, Paris\/European Observatory on Health Systems and Policies, Brussels."},{"issue":"7","key":"1365_CR3","doi-asserted-by":"publisher","first-page":"e0180010","DOI":"10.1371\/journal.pone.0180010","volume":"12","author":"N Tangri","year":"2017","unstructured":"Tangri N, Ferguson TW, Whitlock RH, Rigatto C, Jassal DS, Kass M, et al. Long term health outcomes in patients with a history of myocardial infarction: a population based cohort study. PLoS One. 2017;12(7):e0180010.","journal-title":"PLoS One."},{"issue":"11","key":"1365_CR4","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1093\/aje\/kwh147","volume":"159","author":"M Jokhadar","year":"2004","unstructured":"Jokhadar M, Jacobsen SJ, Reeder GS, Weston SA, Roger VL. Sudden death and recurrent ischemic events after myocardial infarction in the community. Am J Epidemiol. 2004;159(11):1040\u20136.","journal-title":"Am J Epidemiol."},{"issue":"12","key":"1365_CR5","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1001\/jama.2010.1322","volume":"304","author":"DL Bhatt","year":"2010","unstructured":"Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304(12):1350\u20137.","journal-title":"JAMA."},{"issue":"8","key":"1365_CR6","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1093\/eurheartj\/ehab892","volume":"43","author":"A Timmis","year":"2022","unstructured":"Timmis A, Vardas P, Townsend N, Torbica A, Katus H, De Smedt D, et al. European Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J. 2022;43(8):716\u201399.","journal-title":"Eur Heart J."},{"issue":"12","key":"1365_CR7","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","volume":"316","author":"MG Silverman","year":"2016","unstructured":"Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316(12):1289\u201397.","journal-title":"JAMA."},{"issue":"45","key":"1365_CR8","doi-asserted-by":"publisher","first-page":"3478-90a","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Eur Heart J. 2013;34(45):3478-90a.","journal-title":"Eur Heart J."},{"issue":"1","key":"1365_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J."},{"issue":"39","key":"1365_CR10","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K, M\u00fcller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043\u2013140.","journal-title":"Eur Heart J."},{"issue":"25","key":"1365_CR11","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397.","journal-title":"N Engl J Med."},{"issue":"2","key":"1365_CR12","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.atherosclerosis.2012.02.016","volume":"223","author":"D Morrone","year":"2012","unstructured":"Morrone D, Weintraub WS, Toth PP, Hanson ME, Lowe RS, Lin J, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223(2):251\u201361.","journal-title":"Atherosclerosis."},{"issue":"8","key":"1365_CR13","first-page":"746","volume":"58","author":"A Catapano","year":"2013","unstructured":"Catapano A, Toth PP, Tomassini JE, Tershakovec AM. The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups. Clin Lipidol. 2013;58(8):746\u201355.","journal-title":"Clin Lipidol."},{"issue":"3","key":"1365_CR14","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1161\/HYPERTENSIONAHA.118.11609","volume":"72","author":"JA Lamprea-Montealegre","year":"2018","unstructured":"Lamprea-Montealegre JA, Zelnick LR, Hall YN, Bansal N, De Boer IH. Prevalence of hypertension and cardiovascular risk according to blood pressure thresholds used for diagnosis. Hypertension. 2018;72(3):602\u20139.","journal-title":"Hypertension."},{"key":"1365_CR15","doi-asserted-by":"publisher","first-page":"6635345","DOI":"10.1155\/2021\/6635345","volume":"2021","author":"A Alborzi","year":"2021","unstructured":"Alborzi A, Attar A, Sayadi M, Nouri F. The effects of intensive blood pressure control on cardiovascular outcomes based on 10-year ASCVD risk score: an analysis of a clinical trial. Cardiol Res Pract. 2021;2021:6635345.","journal-title":"Cardiol Res Pract."},{"issue":"3","key":"1365_CR16","first-page":"CD009868","volume":"3","author":"E Bahiru","year":"2017","unstructured":"Bahiru E, de Cates AN, Farr MRB, Jarvis MC, Palla M, Rees K, et al. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. Cochrane Database Syst Rev. 2017;3(3):CD009868.","journal-title":"Cochrane Database Syst Rev"},{"issue":"8 Pt 2","key":"1365_CR17","doi-asserted-by":"publisher","first-page":"752","DOI":"10.7326\/0003-4819-127-8_Part_2-199710151-00063","volume":"127","author":"XH Zhou","year":"1997","unstructured":"Zhou XH, Melfi CA, Hui SL. Methods for comparison of cost data. Ann Intern Med. 1997;127(8 Pt 2):752\u20136.","journal-title":"Ann Intern Med."},{"key":"1365_CR18","doi-asserted-by":"crossref","unstructured":"Chambers JM, Freeny AE, Heiberger RM. Analysis of variance; designed experiments. Statistical Models in S. 2017.","DOI":"10.1201\/9780203738535-5"},{"issue":"4","key":"1365_CR19","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/2047487320949414","volume":"28","author":"PA Cortesi","year":"2021","unstructured":"Cortesi PA, Fornari C, Madotto F, Conti S, Naghavi M, Bikbov B, et al. Trends in cardiovascular diseases burden and vascular risk factors in Italy: the Global Burden of Disease study 1990\u20132017. Eur J Prev Cardiol. 2021;28(4):385\u201396.","journal-title":"Eur J Prev Cardiol."},{"issue":"1","key":"1365_CR20","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1186\/s12872-023-03518-y","volume":"23","author":"K Carlsson","year":"2023","unstructured":"Carlsson K, Nilsson K, Wolden ML, Faurby M. Economic burden of atherosclerotic cardiovascular disease: costs related to healthcare and loss of productivity; a matched case-control study in more than 450,000 Swedish individuals. BMC Cardiovasc Disord. 2023;23(1):483.","journal-title":"BMC Cardiovasc Disord."},{"issue":"6","key":"1365_CR21","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s11606-009-1240-1","volume":"25","author":"JE Bailey","year":"2010","unstructured":"Bailey JE, Wan JY, Tang J, Ghani MA, Cushman WC. Antihypertensive medication adherence, ambulatory visits, and risk of stroke and death. J Gen Intern Med. 2010;25(6):495\u2013503.","journal-title":"J Gen Intern Med."},{"issue":"5","key":"1365_CR22","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg L, Blaschke T. Drug therapy: adherence to medication. N Engl J Med. 2005;353(5):487\u201397.","journal-title":"N Engl J Med."},{"issue":"12","key":"1365_CR23","first-page":"1529","volume":"26","author":"DR Axon","year":"2020","unstructured":"Axon DR, Vaffis S, Chinthammit C, Lott BE, Taylor AM, Pickering M, et al. Assessing the association between medication adherence, as defined in quality measures, and disease-state control, health care utilization, and costs in a retrospective database analysis of Medicare supplemental beneficiaries using statin medications. J Manag Care Spec Pharm. 2020;26(12):1529\u201337.","journal-title":"J Manag Care Spec Pharm."},{"issue":"1","key":"1365_CR24","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s12325-021-01960-y","volume":"39","author":"P Sciattella","year":"2022","unstructured":"Sciattella P, Maggioni AP, Arcangeli E, Sidelnikov E, Kahangire DA, Mennini FS. Healthcare resource utilization, cardiovascular event rate and use of lipid-lowering therapies in secondary prevention of ASCVD in hospitalized patients in Italy. Adv Ther. 2022;39(1):314\u201327.","journal-title":"Adv Ther."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01365-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-024-01365-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01365-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T16:18:19Z","timestamp":1729700299000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-024-01365-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,9]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1365"],"URL":"https:\/\/doi.org\/10.1007\/s40261-024-01365-z","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,9]]},"assertion":[{"value":"30 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Figure 2 has been updated","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Universit\u00e0 degli Studi di Roma Tor Vergata within the CRUI-CARE Agreement. This study was funded by Servier Group Italy. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Francesco S. Mennini, Matteo Scortichini, Paolo Sciattella, and Furio Colivicchi have no relevant financial or non-financial interests to disclose. Aldo P. Maggioni received personal fees for participating in committees of studies supported by Bayer, AstraZeneca, Novartis, and Sanofi outside the present work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"According to the rules from the Italian Medicines Agency (available at ), retrospective studies using administrative databases do not require Ethics Committee protocol approval.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"According to the General Authorization for the Processing of Personal Data for Scientific Research Purposes issued by the Italian Privacy Authority on 10 August, 2018 (available at ), this study was exempt from informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request and with permission of the Marche region and LHU Umbria 2.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The R code is available from the corresponding author on reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to the study conception. PS and FSM developed the study design, PS and MS conducted the statistical analysis and derived the analytical results. The first draft of the manuscript was written by MS and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}